Frenkel Ran 4
4 · Karyopharm Therapeutics Inc. · Filed Feb 17, 2021
Insider Transaction Report
Form 4
Frenkel Ran
EVP, WW Development Operations
Transactions
- Exercise/Conversion
Restricted Stock Units
2021-02-15−9,675→ 19,350 total→ Common Stock (9,675 underlying) - Sale
Common Stock
2021-02-11$15.52/sh−2,046$31,752→ 39,338 total - Exercise/Conversion
Common Stock
2021-02-15+9,675→ 49,013 total
Footnotes (4)
- [F1]This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
- [F2]The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.
- [F3]Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.
- [F4]On February 15, 2019, the reporting person was granted 38,700 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.